226 related articles for article (PubMed ID: 18298902)
1. Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples.
Tsui KH; Juang HH; Lee TH; Chang PL; Chen CL; Yung BY
Acta Pharmacol Sin; 2008 Mar; 29(3):364-70. PubMed ID: 18298902
[TBL] [Abstract][Full Text] [Related]
2. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY
Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of nucleophosmin/B23 and human epidermal growth factor receptor 2/neu expressions in gastric cancers.
Zhou F; Qiu W; Sun L; Xiang J; Sun X; Sui A; Ding A; Yue L
APMIS; 2013 Jul; 121(7):582-91. PubMed ID: 23489260
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy.
Jahnson S; Karlsson MG
J Urol; 1998 Oct; 160(4):1291-6. PubMed ID: 9751338
[TBL] [Abstract][Full Text] [Related]
7. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS
J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
[TBL] [Abstract][Full Text] [Related]
8. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
9. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
10. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
[TBL] [Abstract][Full Text] [Related]
11. The risk factor for urethral recurrence after radical cystectomy in patients with transitional cell carcinoma of the bladder.
Cho KS; Seo JW; Park SJ; Lee YH; Choi YD; Cho NH; Yang SC; Hong SJ
Urol Int; 2009; 82(3):306-11. PubMed ID: 19440019
[TBL] [Abstract][Full Text] [Related]
12. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes.
Boudreaux KJ; Chang SS; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Clark PE
Cancer; 2009 Feb; 115(4):770-5. PubMed ID: 19152431
[TBL] [Abstract][Full Text] [Related]
13. Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer.
Stein JP; Penson DF; Lee C; Cai J; Miranda G; Skinner DG
J Urol; 2009 May; 181(5):2052-8; discussion 2058-9. PubMed ID: 19286213
[TBL] [Abstract][Full Text] [Related]
14. Ras-dependent recruitment of c-Myc for transcriptional activation of nucleophosmin/B23 in highly malignant U1 bladder cancer cells.
Yeh CW; Huang SS; Lee RP; Yung BY
Mol Pharmacol; 2006 Oct; 70(4):1443-53. PubMed ID: 16857742
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of static cytometry in transitional cell carcinoma of the bladder: recurrence rate and survival in a group of patients at 10 years follow-up.
Cai T; Margallo E; Nesi G; Giubilei G; Rizzo M; Bartoletti R
Oncol Rep; 2006 Jan; 15(1):213-9. PubMed ID: 16328058
[TBL] [Abstract][Full Text] [Related]
16. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors.
Palou J; Rodríguez-Rubio F; Millán F; Algaba F; Rodríguez-Faba O; Huguet J; Villavicencio H
Urology; 2009 Jun; 73(6):1313-7. PubMed ID: 19362341
[TBL] [Abstract][Full Text] [Related]
17. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Wolff I; Schostak M; Tabiti K; Müller M; Miller K; Schrader M
Cancer Lett; 2007 Jan; 245(1-2):121-6. PubMed ID: 16473461
[TBL] [Abstract][Full Text] [Related]
18. XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer.
Li M; Song T; Yin ZF; Na YQ
Chin Med J (Engl); 2007 Mar; 120(6):469-73. PubMed ID: 17439739
[TBL] [Abstract][Full Text] [Related]
19. [Correlation of clusterin expression to prognosis of bladder carcinoma].
Luo JH; Xie D; Chen W; Dai YP; Li XF; Tao Y; Zheng KL
Ai Zheng; 2005 Jun; 24(6):743-7. PubMed ID: 15946493
[TBL] [Abstract][Full Text] [Related]
20. Presentation, location and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
Dhar NB; Jones JS; Reuther AM; Dreicer R; Campbell SC; Sanii K; Klein EA
BJU Int; 2008 Apr; 101(8):969-72. PubMed ID: 18005201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]